Core One Labs

Core One Labs is a Canadian life sciences biotechnology company focused on the research, development, and production of biologically synthesized cGMP API grade psychedelic compounds. The company aims to become a vertically integrated large-scale supplier of these compounds to both individuals and corporations. Core One Labs operates through three business units: psychedelic compound production (Vocan, Awaken, GMP Drug Inc.), drug development (Akome), and medical clinics (Rejuva Mental Health Clinic, Bluejay Medical, Shahcor clinics). The company is developing a pipeline of patent-pending, cost-effective cGMP psychedelic compounds for mental health and neurological disorders research.

Core One Labs is publicly traded on the Canadian Securities Exchange under the symbol ‘COOL,’ on the OTC under ‘CLABF,’ and on the Borse Frankfurt Exchange under ‘LD6, WKN: A3CSSU’. The company has developed a proprietary psilocybin production system using engineered bacteria through its subsidiary Vocan Biotechnologies Inc., which has filed for patent protection. Vocan Biotechnologies operates a state-of-the-art research facility and has successfully tested its proof of concept for the biosynthesis of psilocybin, potentially reducing production costs significantly.

Core One Labs holds four provisional patents for psychedelic-based pharmaceutical formulations through its subsidiary Akome Biotech Ltd., which is investigating plant bioactive and psychedelic compounds for neurological disorders. Additionally, Awakened Biosciences Inc., another subsidiary, has developed novel synthetic technologies for psilocybin and psilocin production and has filed three provisional patent applications. Core One Labs also has an interest in four medical clinics with a combined database of over 275,000 patients.